A 2023 review notes that it is a colloquial term, which spread as patients and clinicians reported less rumination and preoccupation about food on GLP-1 medicines such as semaglutide.1 A 2025 advisory from four medical societies uses the term for preoccupation with food and lists its reduction among the effects of these medicines.2
What researchers call it
Because food noise is not a clinical term, the 2023 review looks at it through an established research concept: food cue reactivity, the way people respond to food cues. Those cues can be external or internal. The authors propose a model they call CIRO, for Cue, Influencer, Reactivity and Outcome. It sets out the factors that decide how strongly a person reacts to a food cue, and how that reaction shapes eating in the short and the long term. They offer it as a framework for future studies of food noise.1
What the appetite trials measured
No trial has used food noise as its outcome, but appetite trials measure the pieces of it. People eat at will at a test meal or over a test day, and fill in questionnaires on hunger, cravings and control over eating:
- Semaglutide 1 mg, 12 weeks: 30 adults with obesity ate 24% less over a test day, about 726 kcal.3
- Semaglutide 2.4 mg, 20 weeks: 72 adults with obesity ate 35% less at a test lunch, 1,736 against 2,676 kJ, about 415 against 640 kcal. They reported less hunger, more fullness, better control of eating and fewer and weaker food cravings. Weight fell by 9.9% on semaglutide and 0.4% on placebo.4
- Oral semaglutide 14 mg, 12 weeks: 13 adults with type 2 diabetes ate 38.9% less over a test day, about 1,218 kcal.5
- Tirzepatide 15 mg, 28 weeks: 45 adults with type 2 diabetes ate 310 kcal less at a test lunch.6
The advisory sums up the wider research the same way: less preoccupation with food, less emotional eating, less eating in response to outside triggers, and fewer binge episodes. Its authors add from their own clinics that many patients become less interested in food.2
What changes besides the amount
The trials also saw shifts in what people preferred. In the 12-week trial of semaglutide 1 mg, people on the drug showed a lower preference for high-fat foods.3 In the trial of oral semaglutide, a fat-rich breakfast left people fuller and less hungry on the drug than on placebo, while a standard breakfast showed no reliable difference.5 Outside the lab, a food-record study of 69 people who had used a GLP-1 for at least a month found an average intake of 1,748 kcal a day, 1,700 for women and 1,933 for men. Added sugars averaged 11.5 g a day, far under the 50 g reference.7
None of these studies asked people about food noise by name or measured it directly. What they show is the set of changes that people describe with this popular term: less hunger, fewer cravings, smaller meals and more control.
The flip side
The advisory also names the cost. When food stops being interesting, it becomes easy to eat too little or too narrowly. A large, rapid drop in intake can leave too few essential vitamins and minerals, especially below 1,200 kcal a day for women and 1,800 for men.2 Our page on what to eat on a GLP-1 covers how to keep meals complete when appetite is low.
Sources
- Hayashi D, Edwards C, Emond JA, et al. What is food noise? A conceptual model of food cue reactivity. Nutrients 2023;15:4809. doi:10.3390/nu15224809
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
- Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017;19:1242-1251. doi:10.1111/dom.12932
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754-762. doi:10.1111/dom.14280
- Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab 2021;23:581-588. doi:10.1111/dom.14255
- Heise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 2023;46:998-1004. doi:10.2337/dc22-1710
- Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R, Jones R. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr 2025;12:1566498. doi:10.3389/fnut.2025.1566498
Related analyses
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
How much protein to eat on Zepbound or Wegovy: the targets, calculated for your weight
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Zepbound plateau: when weight loss slows, why, and what the trials show
Rate your food thoughts from 0 to 10 each day next to your dose, and watch the trend.
Open Dose Insider